Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 5

1.

Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group.

Fein AM, Bernard GR, Criner GJ, Fletcher EC, Good JT Jr, Knaus WA, Levy H, Matuschak GM, Shanies HM, Taylor RW, Rodell TC.

JAMA. 1997 Feb 12;277(6):482-7.

PMID:
9020273
2.

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.

Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, Cron RQ, Opal SM.

Crit Care Med. 2016 Feb;44(2):275-81. doi: 10.1097/CCM.0000000000001402.

PMID:
26584195
4.

[A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsis].

Hernández M.

Rev Chilena Infectol. 2016 Jun;33(3):359. doi: 10.4067/S0716-10182016000300021. Spanish. No abstract available.

5.

Retraction Note: Diacerhein attenuates the inflammatory response and improves survival in a model of severe sepsis.

Calisto KL, Camacho AC, Mittestainer FC, Carvalho BM, Guadagnini D, Carvalheira JB, Saad MJ.

Crit Care. 2016 Sep 1;20(1):278. No abstract available.

Supplemental Content

Write to the Help Desk